宮頸癌患者血清可溶性B7-H4檢測及臨床意義

胡國艷,鄭淑華,劉 偉,劉學(xué)軍,呂 晶,王小梅,徐軍發(fā)*

(1.廣州市精神病醫(yī)院 檢 驗科,廣東廣州 510370;2.廣東醫(yī)學(xué)院臨床免疫學(xué)教研室,廣東東莞 523808;3.廣東醫(yī)學(xué)院第一附屬醫(yī)院檢驗科,廣東湛江 524001)

宮頸癌患者血清可溶性B7-H4檢測及臨床意義

胡國艷1,2,鄭淑華2,劉 偉2,劉學(xué)軍1,呂 晶2,王小梅3,徐軍發(fā)2*

(1.廣州市精神病醫(yī)院 檢 驗科,廣東廣州 510370;2.廣東醫(yī)學(xué)院臨床免疫學(xué)教研室,廣東東莞 523808;3.廣東醫(yī)學(xué)院第一附屬醫(yī)院檢驗科,廣東湛江 524001)

目的探討宮頸癌患者血清可溶性B7-H4的水平及臨床意義。方法在建立了檢測可溶性B7-H4(sB7-H4)ELISA夾心法的檢測50例宮頸癌患者、40例子宮肌瘤患者血清sB7-H4水平,以50例體檢健康者血清sB7-H4水平為對照。結(jié)果正常體檢者、子宮肌瘤患者和宮頸癌患者血清 sB7-H4濃度分別為(31.62±9.85)μ g/L、(34.49±8.17)μ g/L和(43.70±8.60)μ g/L。對照組者與子宮肌瘤患者血清sB7-H4水平差異無顯著性(P＞0.05),宮頸癌患者血清sB7-H4水平顯著高于對照組和子宮肌瘤患者(P均＜0.01)。手術(shù)前宮頸癌患者血清sB7-H4水平(46.88±8.89)μ g/L明顯高于術(shù)后患者(39.29±5.99)μ g/L(P＜0.01)。宮頸癌患者血清sB7-H4水平與鱗狀上皮癌腫瘤(SCC)水平呈正相關(guān)(P＜0.01)。結(jié)論sB7-H4與宮頸癌的發(fā)病有關(guān),可能是宮頸癌的一種較好的腫瘤標志物,檢測sB7-H4對宮頸癌的輔助診斷和療效觀察具有一定的臨床意義。

宮頸癌;子宮肌瘤;sB7-H4

(Chin J Lab Diagn,2010,14:1425)

B7-H4是2003年發(fā)現(xiàn)的B7家族成員,在T細胞介導(dǎo)的免疫中起負調(diào)節(jié)作用,主要表現(xiàn)為抑制T細胞的增殖、G0/G1期的細胞周期進程和IL-2的產(chǎn)生[1]。B7-H4在正常組織中無表達或有極低水平表達,但已經(jīng)發(fā)現(xiàn)在多種腫瘤組織中高表達,如卵巢癌[2]、肺癌[3]、腎細胞癌[4]、乳腺癌[5]、子宮內(nèi)膜癌[6]、胰腺癌[7]和前列腺癌[8],并發(fā)現(xiàn)卵巢癌等患者血清中可溶性B7-H4(soluble B7-H4,sB7-H4)水平的增高[2],但有關(guān)可溶性B7-H4與宮頸癌的關(guān)系未見報道。本研究在建立了檢測可溶性B7-H4 ELISA夾心法[9]的基礎(chǔ)上對部分健康體檢者和子宮肌瘤患者與宮頸癌患者血清B7-H4水平進行了檢測。

1 材料與方法

1.1 實驗對象 宮頸癌組50例,子宮肌瘤40例,均來自廣東醫(yī)學(xué)院附屬醫(yī)院腫瘤科,所有經(jīng)病理檢查確診,50例宮頸癌中Ⅰ期患者17例,Ⅱ期患者25例,Ⅲ、Ⅳ期患者8例,手術(shù)前 29例,手術(shù)后21例,患者年齡31-77歲,平均年齡(50.18±10.50)歲。40例子宮肌瘤中,患者年齡 30-57歲,平均年齡(42.56±6.59)歲。健康對照組50例,來自廣東醫(yī)學(xué)院附屬醫(yī)院體檢中心體檢健康者標本,男29例、女21例,年齡18-67歲,平均年齡(45.65±11.38)歲,經(jīng)體檢無異常。

1.2 材料 酶聯(lián)微量反應(yīng)板,來源于Coning公司?？谷薆7-H4單克隆抗體(mAb),購自eBioscience公司。重組小鼠B7-H4蛋白及兔抗小鼠B7-H4多克隆抗體由本室制備[9]。HRP標記羊抗兔IgG,購自北京博奧森生物技術(shù)有限公司。TMB底物及顯色劑,沈陽惠民公司產(chǎn)品。BIOTEK Elx800型酶標儀等。SCC試劑盒為瑞典CanAg公司產(chǎn)品。

1.3 雙抗體夾心間接ELISA檢測方法 用0.05 mol/L pH9.6的碳酸鹽緩沖液按1∶2 000稀釋抗人B7-H4mAb,包被可拆酶標板,置4℃過夜,用PBST洗滌3次。采用100 ml/L FCS封閉,200μ L/孔,37℃作用2 h后用PBST洗滌3次。用PBST-BSA將200 mg/L重組小鼠B7-H4從1∶1 000做倍比稀釋至1∶64 000作為標準品。在包被好的酶標板中加入標準品或待測血清標本100 μ L/孔。37℃作用 1 h,用PBST洗3次。加入1∶1 000稀釋兔抗小鼠B7-H4多克隆抗體,100 μ L/孔,37℃作用1 h后用PBST洗3次,再加入1∶5 000稀釋HRP標記羊抗兔 IgG,37℃作用1 h 后用 PBST洗 3 次,按100 μ L/孔加顯色底物,作用15min,以2 mol/L硫酸終止,在酶標儀上測A450值。

1.4 樣本收集與檢測 被檢者在早上空腹采血,靜置1 h后,分離血清,小量分裝,置-70℃保存?zhèn)錅y。所有樣本均在同一批次檢測,每個樣本設(shè)立兩個平行檢測,取平均A值計算樣本中 sB7-H4的含量。SCC相關(guān)抗原檢測由廣州市精神病醫(yī)院檢驗科完成。

2 結(jié)果

2.1 宮頸癌、子宮肌瘤患者及健康體檢者血清sB7-H4水平

宮頸癌、子宮肌瘤患者及健康體檢者血清sB7-H4水平見圖 1,宮頸癌患者血清 sB7-H4水平[(43.70±8.60)μ g/L]顯著高于子宮肌瘤患者[(34.50±8.17)μ g/L](t=4.106,P＜0.001)和健康體檢者[(31.62±9.85)μ g/L](t=5.235,P＜0.001),而子宮肌瘤組與健康體檢者對照組相比無統(tǒng)計學(xué)意義(t=1.881,P＞0.05)。

圖1 宮頸癌、子宮肌瘤患者及健康體檢者血清sB7-H4

2.2 術(shù)前和術(shù)后宮頸癌患者血清sB7-H4水平的比較

結(jié)果見表2。結(jié)果顯示,癌術(shù)前宮頸患者血清sB7-H4水平顯著高于后術(shù)患者,差異有顯著性意義(t=3.390,P＜0.05)。

表2 術(shù)前和術(shù)后宮頸癌患者血清B7-H4水平

2.3 不同臨床分期宮頸癌患者血清sB7-H4水平的變化

表3顯示,不同臨床分期宮頸癌患者隨著病情加重血清sB7-H4水平有增高趨勢,經(jīng)方差分析,各組間比較差異無顯著性(F=2.444,P＞0.05)。

表3 宮頸癌術(shù)前和術(shù)后血清B7-H4檢測結(jié)果

2.4 宮頸癌患者血清B7-H4水平與SCC相關(guān)性

將50例宮頸癌患者血清sB7-H4水平與SCC水平進行單因素直線相關(guān)分析,結(jié)果顯示sB7-H4水平與SCC水平呈正相關(guān)(r=0.632,P＜0.01)。

3 討論

子宮頸癌是婦科最常見的惡性腫瘤之一。在全球范圍內(nèi),每年約有20多萬女性死于宮頸癌。在發(fā)展中國家,宮頸癌則屬于常見多發(fā)的婦科腫瘤,排行榜首。宮頸癌早期沒有任何癥狀,當宮頸癌的癥狀出現(xiàn)三個月后就診者已有2/3為癌癥晚期。

B7-H4于2003年被發(fā)現(xiàn)后,各種關(guān)于B7-H4與腫瘤關(guān)系的研究越來越多,研究發(fā)現(xiàn)多種腫瘤組織高表達B7-H4,如卵巢癌、腎細胞癌、非小細胞性肺癌、乳腺癌和前列腺癌[2-11]等,在前列腺癌[8]、乳腺癌[11]、腎癌[4]、非小細胞性肺癌[3]中 B7-H4的表達與腫瘤的分型、分期和病人的轉(zhuǎn)歸密切相關(guān),而且在肺癌和前列腺癌中B7-H4的表達與腫瘤的轉(zhuǎn)移相關(guān),高表達B7-H4的前列腺癌更容易擴散、復(fù)發(fā),患者死亡率也高[8],因此B7-H4被認為是一種較敏感的腫瘤標志物。但以上研究主要是基于腫瘤組織的免疫組化染色得到的結(jié)果,對于血清中可溶性B7-H4的檢測少見有報道,我們用本室建立的檢測可溶性B7-H4 ELISA夾心法對部分體檢健康者、子宮肌瘤患者與宮頸癌患者血清B7-H4水平進行了檢測,結(jié)果發(fā)現(xiàn)宮頸癌患者血清B7-H4水平與健康體檢者和子宮肌瘤患者B7-H4水平的差異有統(tǒng)計學(xué)意義,而健康體檢者與子宮肌瘤患者之間B7-H4水平差異無統(tǒng)計學(xué)意義,而且宮頸癌患者血清B7-H4水平與SCC水平呈正相關(guān),提示B7-H4與宮頸癌的發(fā)病有關(guān),對于鑒別子宮良、惡性腫瘤有一定的意義,可能是宮頸癌的一種較好的腫瘤標志物。我們的結(jié)果也表明術(shù)后宮頸癌患者血清sB7-H4水平顯著低于術(shù)前患者,提示宮頸癌患者血清sB7-H4水平與治療狀況相關(guān)。宮頸癌患者血清sB7-H4水平與腫瘤的臨床分期無顯著相關(guān)性,可能與本研究觀察病例偏少有關(guān)。本研究結(jié)果提示血清sB7-H4水平的檢測對宮頸癌的輔助診斷和療效觀察具有一定的臨床意義。

[1]Kryczek I,Wei S,Zou L,et al.Cutting edge:induction of B7-H4 on APCs through IL-10:novel suppressive mode for regulatory T cells[J].J Immunol,2006,177(1):40.

[2]Simon I,Zhuo S,Corral L,et al.B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer[J].Cancer Res,2006,66(3):1570.

[3]Sun Y,Wang Y,Zhao J,et al.B7-H3 and B7-H4 expression in non-smallcell lung cancer[J].Lung cancer,2006,53(2):143.

[4]Krambeck A E,Thompson R H,Dong H,et al.B7-H4 expression in renal cell carcinoma and tumor vasculature:associationswith cancer progression and survival[J].Proc Natl Acad Sci,USA,2006,103(27):10391.

[5]Salceda S,Tang T,Kmet M,et al.The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation[J].Exp Cell Res,2005,306(1):128.

[6]Miyatake T,Tringler B,Liu w,et al.B7-H4(DD-O110)is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration[J].Gynecol Oncol,2007,106(1):119.

[7]Awadallah N S,Shroyer K R,Langer D A,et al.Detection of B7-H4 and p53 in pancreatic cancer:potential role as a cytological diagnostic adjunct[J].Pancreas,2008,36(2):200.

[8]Zang X,Thompson R H,Al-Ahmadie H A,et al.B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome[J].Proc Natl Acad Sci U S A,2007,104(49):19458.

[9]胡國艷,鄭淑華,劉 偉,等.檢測可溶性 B7-H4 ELISA夾心法的建立[J].細胞與分子免疫學(xué)雜志,2008,24(8):831.

[10]Kryczek I,Zou L,Rodriguez P,Zhu G,et al.B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma[J].J Exp Med,2006,203(4):871.

[11]Tringler B,Zhuo S,Pilkington G,et al.B7-H4 is highly expressed in ductal and lobular breast cancer[J].Cli Cancer Res,2005,11(5):1842.

Clinical significance of determination of serum B7-H4 in patients with uterine cervix cancer

HU Guo-yan1,2,ZHENGShuhua2,LIU Wei2,et al.(1.Department of clinical laboratory,Guangzhou psychiatric hospital,Guangzhou510370;2.Department of Clinical Immunology,Guangdong Medical College,Dongguan523808,China)

ObjectiveTo study the clinical significance of determination of serum B7-H4 in patientswith uterine cervix cancer.MethodsSerum B7-H4 levelswere determined in 50 patients with uterine cervix cancer and 40 patients with uterine fibroid as well as in 35 controls.ResultsThe serum B7-H4 levels in patients with uterine cervix cancer(43.70 ±8.60 μ g/L)were significantly higher than those in patientswith uterine fibroid(36.63±7.70μ g/L)and healthy controls(31.62±9.85μ g/L)(P＜0.01).But the B7-H4 in serum were not significant between patients with uterine fibroid and healthy controls(P＞0.05).The serum B7-H4 levels in patientswithuterine cervix cancer before surgical treatment(46.65±8.59μ g/L)washigher than that in patientswithuterine cervix cancer after surgical treatment(38.45±9.33μ g/L)(P＜0.01).There was correlation between the serum B7-H4 levels in patients with uterine cervix cancer and the serum SCC levels in patients with uterine cervix cancer(P＜0.05).ConclusionThese results suggest that the B7-H4 may correlationwith uterine cervix cancer.B7-H4 may be a new marker of diagnosis for uterine cervix cancer.Measurement of serum B7-H4,not only provide useful information for distinctive diagnosisof different kindsof uterine diseases,but also is a good target in evaluation of disease extent and effect of treatments in patients with uterine cervix cancer.

uterine cervix cancer;uterine fibroid;B7-H4

R730.3

A

1007-4287(2010)09-1425-03

國家自然科學(xué)基金(30922779),廣東省社會發(fā)展計劃項目(2006B36002021),東莞市科技計劃項目(2008108101054)

*通訊作者

胡國艷(1976-),女,湖南石門人,主管檢驗師。

2009-11-11)